Hemp-derived consumer products have expanded into nearly every corner of the wellness market. Gummies, infused beverages, tinctures, vape products, topical creams, and dietary supplements all offer manufacturers opportunities to turn cannabinoid extracts into finished consumer goods. But these products do not face the same regulatory risks.
Their legal status depends on more than the source of the hemp or the concentration of delta-9 THC. The intended use, cannabinoid composition, manufacturing process, product claims, packaging, distribution model, and applicable federal and state laws can all affect whether a product can legally be manufactured and sold.
For manufacturers, the challenge is becoming more urgent. Changes to the federal definition of hemp, continuing questions about Food and Drug Administration (FDA) oversight, and state-specific restrictions are creating uncertainty for companies deciding which products to develop, where to manufacture them, and how to distribute them.
The products facing the greatest uncertainty are generally those that combine intoxicating cannabinoids with food, inhalation, or other heavily regulated consumer-product categories. However, products containing non-intoxicating cannabinoids are not automatically exempt from regulatory scrutiny.
Understanding the differences between product categories is essential for managing compliance costs, protecting inventory, and making sound manufacturing investments.
Why the Federal Hemp Definition Matters
The 2018 Farm Bill established a federal definition of hemp based on a delta-9 THC concentration of no more than 0.3% on a dry-weight basis. That distinction helped create a market for hemp-derived ingredients and products, including cannabinoid extracts.
However, hemp’s exclusion from the federal definition of marijuana did not remove FDA authority over foods, dietary supplements, cosmetics, or drugs containing hemp-derived compounds.
FDA
+1
The regulatory landscape is also changing. A 2025 federal law narrowed the hemp definition and established restrictions affecting many hemp-derived cannabinoid products, with the implementation of most of the new restrictions scheduled for December 11, 2026. The changes include a low limit for combined total THC and certain similar-effect cannabinoids in final products, as well as restrictions affecting certain cannabinoids manufactured outside the plant.
AP News
For businesses, this creates two separate compliance questions:
- Does the ingredient or finished product qualify as hemp under the applicable federal definition?
- Even if it qualifies as hemp, can it legally be marketed in its intended product category?
A positive answer to the first question does not guarantee a positive answer to the second.
Comparing the Six Major Hemp Product Categories
- Gummies
Very high uncertainty
Gummies combine several regulatory challenges: edible-product rules, cannabinoid limits, dosage consistency, child safety, labeling, and the possibility of being mistaken for ordinary candy.
FDA has specifically raised concerns about CBD-containing gummies and other foods that resemble products commonly eaten by children.
FDA
Manufacturing impact: Formulation changes can affect potency uniformity, flavor, texture, stability, packaging, and serving size. If a product exceeds the applicable federal hemp limit, changing the label alone will not resolve the issue.
- Beverages
Very high uncertainty
Hemp-derived THC beverages face both cannabinoid restrictions and questions about whether the active ingredient can legally be added to a conventional food or drink. FDA’s stated position is that adding THC or CBD to conventional foods for human consumption is prohibited under the applicable provisions of federal food law.
U.S. Food and Drug Administration
+1
Manufacturing impact: Companies must evaluate cannabinoid solubility, emulsion stability, dose uniformity, shelf life, packaging compatibility, and whether the intended formulation is legally marketable. A technically stable beverage is not necessarily a legally compliant one.
- Tinctures and oral drops
Very high uncertainty
Tinctures can be marketed in ways that create different regulatory questions. A product intended to be swallowed, a product intended for use in the mouth, and a product making therapeutic claims may not follow the same regulatory pathway.
CBD and THC products cannot simply be marketed as dietary supplements under FDA’s current stated interpretation of the Federal Food, Drug, and Cosmetic Act.
U.S. Food and Drug Administration
+1
Manufacturing impact: Companies should document intended use, route of administration, ingredient identity, concentration, serving size, dropper accuracy, stability, and all label and website claims. Calling a product a “tincture” does not determine its legal classification.
- Vapes and inhalable products
Very high uncertainty
Vapes face overlapping questions involving cannabinoid legality, inhalation safety, device regulation, chemical conversion, state restrictions, and product testing. Certain products may also fall under FDA tobacco-product authorities depending on their ingredients, intended use, and device or product configuration; not every cannabinoid vape follows the same regulatory pathway.
The revised federal hemp definition adds further concern for certain cannabinoids manufactured outside the plant.
AP News
+1
Manufacturing impact: Operators need validated specifications for cannabinoid identity, residual solvents, contaminants, formulation ingredients, device compatibility, and batch consistency. They must also verify whether their particular product can legally be manufactured and sold in each intended market.
- Topicals, creams, and balms
Variable uncertainty
Topicals may have a different regulatory pathway from ingestible products, particularly when they are conventional cosmetics intended for uses such as moisturizing or cleansing. But a topical is not automatically exempt from federal hemp restrictions or FDA oversight.
Intended use matters. A product promoted to treat pain, inflammation, or a disease may be regulated as a drug rather than solely as a cosmetic.
FDA
+1
Manufacturing impact: Businesses should assess cannabinoid concentration, ingredient safety, microbial quality, stability, packaging compatibility, and product claims. Claims on labels, websites, and advertising materials should be reviewed together.
- Dietary supplement products
Very high uncertainty
This category has a particularly important legal distinction: products marketed as dietary supplements containing CBD or THC face a specific obstacle under FDA’s current interpretation of federal law. FDA has stated that it does not intend to pursue rulemaking to permit CBD in conventional foods or dietary supplements under the existing framework.
FDA
+1
Manufacturing impact: Standard supplement practices—including GMP controls, capsule uniformity, ingredient testing, and accurate labeling—do not resolve the underlying question of whether the cannabinoid ingredient may lawfully be marketed in that category.
Which Products Face the Greatest Risk?
The following ranking is a practical assessment of regulatory exposure, not a formal ranking published by a government agency. Actual risk depends on the cannabinoid, formulation, intended use, manufacturing method, and destination market.
| Product category | Principal regulatory concern | Key operational priority |
| THC gummies | Intoxicating cannabinoid limits and food-law issues | Reformulation assessment and packaging review |
| THC beverages | Hemp definition and restrictions on cannabinoid ingredients in food | Legal review before scaling production |
| Oral tinctures | Intended use, supplement classification, and cannabinoid limits | Confirm lawful product pathway |
| Vapes | Cannabinoid status, inhalation safety, and device-specific rules | Ingredient and product compliance review |
| CBD dietary supplements | FDA’s current interpretation of supplement law | Verify legal marketability before investment |
| CBD topicals | Cannabinoid limits, cosmetic requirements, and drug claims | Review formulation and marketing claims |
The revised federal hemp definition could affect products across several of these categories. Consequently, a product that has comparatively fewer issues under one regulatory framework may still face substantial exposure under another.
AP News
+2
The Manufacturing Challenges Behind Regulatory Uncertainty
Regulatory changes rarely affect only the label or the legal department. They can force changes throughout a manufacturing operation.
- Formulation and process validation
A reformulated gummy, beverage, tincture, or topical may behave differently from the original product.
Changes in cannabinoid concentration can affect dispersion, mixing, dose uniformity, stability, and finished-product specifications. Manufacturers should assess whether existing equipment and process parameters remain suitable.
- Testing and quality control
A robust testing program should verify cannabinoid identity and concentration and address applicable contaminants, such as residual solvents, pesticides, heavy metals, and microbial hazards.
The required testing panel should be determined by the product category, applicable law, and destination market. A certificate of analysis alone does not establish that a product is legally marketable.
- Packaging and labeling
A change in product classification may require new labels, warnings, packaging features, or distribution controls.
Companies should maintain version-controlled artwork, approved product specifications, and procedures for removing obsolete packaging from production.
- Inventory and supply-chain exposure
Manufacturers should identify raw materials, extracts, work-in-process, and finished products that could be affected by a regulatory change.
This is especially important for businesses holding large quantities of cannabinoid ingredients or packaging customized for specific formulations.
- Facility utilization and capital investment
Equipment purchased for one product category may still be useful for another, but a change in regulatory status can alter the economics of operating the facility.
Before investing in new extraction, formulation, or filling capacity, management should evaluate alternative product pathways and the licenses or approvals each may require.
A Practical Compliance Plan for Hemp Product Manufacturers
Companies do not need to wait for every regulatory question to be resolved before preparing. They can begin by organizing the information needed to make decisions.
- Classify every SKU. Document its ingredients, cannabinoid profile, intended use, route of administration, claims, and target markets.
- Review the applicable legal framework. Separate hemp-definition requirements from FDA food, drug, supplement, cosmetic, and other applicable requirements.
- Audit suppliers. Confirm cannabinoid identity, manufacturing methods, traceability, specifications, and supporting analytical documentation.
- Evaluate the production process. Determine whether formulation, equipment, testing, packaging, and batch-release controls can support the intended product.
- Model financial exposure. Estimate potential inventory losses, reformulation costs, packaging changes, licensing expenses, and market exits.
- Monitor federal and state developments. Assign responsibility for tracking legal changes and updating procedures, specifications, and product approvals.
The Bottom Line
Hemp products do not all face the same regulatory uncertainty. Gummies and beverages combine cannabinoid restrictions with food-law questions. Oral tinctures and dietary supplement products face important issues involving intended use and FDA’s interpretation of federal law. Vapes add inhalation and device-related considerations, while topicals may have a different pathway depending on their formulation and claims.
The forthcoming federal restrictions add another layer to an already complex environment. Companies should not assume that a product’s existing availability, a supplier’s assurances, or a state-level authorization guarantees continued compliance.
The most defensible strategy is to evaluate each product individually, connect legal requirements to manufacturing controls, and avoid major investments until the intended regulatory pathway is clear.
For the extraction industry, regulatory readiness is not separate from product development. It is part of deciding which products can be manufactured consistently, distributed legally, and sustained commercially.
